Boldenone Undecylenate - Equipoise

Equipoise is the popularly referenced brand name for the veterinary injectable steroid boldenone undecylenate. Specifically it is a derivative of testosterone, which exhibits strong anabolic and moderately androgenic properties. The boldenone undecylenate ester greatly extends the activity of the drug (the undecylenate ester is only one carbon atom longer than decanoate), so that clinically injections would need to be repeated every three or four weeks. In veterinary medicine Equipoise is most commonly used on horses, exhibiting a pronounced effect on lean bodyweight, appetite and general disposition of the animal. This compound is also said to shows a marked ability for increasing red blood cell production, although there should be no confusion that this is an effect characteristic of newly all anabolic/androgenic steroids. The favorable properties of this drug are greatly appreciated by athletes, Equipoise being a very popular injectable in recent years. It is considered by many to be a stronger, slightly more androgenic Deca-Durabolin. It is generally cheaper, and could replace Deca in most cycles without greatly changing the end result.

The side effects associated with Equipoise are generally mild. The structure of boldenone undecylenate does allow it to convert into estrogen, but it does not have an extremely high affinity to do so. To try and quantify this we can look toward aromatization studies, which suggest that its rate of estrogen conversion should be roughly half that of testosterone's. The tendency to develop a noticeable amount of water retention with this drug would therefore be slightly higher than that with Deca-Durabolin (with an estimated 20% conversion), but much less than what would be expected with a stronger agent such as Testosterone. While one does still have a chance of encountering an estrogen related side effect as such when using this substance, it is not a common problem when taken at a moderate dosage level. Gynecomastia might theoretically become a concern, but is usually only heaved of with very sensitive individuals or (again) those venturing high in dosage. Should estrogenic effects become troublesome, the addition of Nolvadex and/or Proviron should of course make the cycle more tolerable. An antiaromatase such as  Arimidex would be stronger options, however probably not indicated with a mild drug as such.

Although it stays active for a much longer time, Equipoise is injected at least once per week by athletes. It is most commonly used at a dosage of 200-400mg (4-8 ml, 50mg version) per week for men, 50-75 mg per week for women. Should a 25mg version be the only product available, the injection volume can become quite uncomfortable. The dosage schedule can be further divided, perhaps injections given every other day to reduce discomfort. One should also take caution to rotate injection sites regularly, so as to avoid irritation or infection. Should too large an oil volume be injected into one site, an abscess may form that requires surgical draining. To avoid such a problem, athletes will usually limit each injection to 3ml and reuse each site no more than once per week, preferably every other week. With Equipoise this may require using not only the gluteus, but also the outer thighs for an injection site. Of course all problems associated with 25mg and 50mg dosed products are eliminated with the newer 100 mg and 200mg/ml versions of this steroid, which clearly give the user much more dosage freedom and injection comfort.